Responsibilities of the team, page-75

Thanks for posting, Rossi.It's great to have everyone's input - even more so when their analysis may differ from mine.

I just don't see any value add in bringing on another Tillet or Andersson. The bases are loaded in my opinion.

You note that a large pharma would wait until we've received our results (assuming Israeli trial). These results aren't due, unless otherwise authorised, for release until the end of 2021. We've got ~40 trial results now - what's one extra?

In what I've read our position sounds almost identical to that of agios in 2010. Only, were holding decades worth of trial data.